Automated 3D echocardiography (3DE) analysis using a new, commercially available algorithm has allowed University of Chicago researchers to accurately quantify left-heart size and function in two-thirds of 300 consecutive patients. They conclude the technology can be useful in clinical practice despite its known workflow-interruptive drawbacks—especially when the echocardiographer has the know-how to correct for its shortcomings.

Treating today’s cancer patient no longer means simply targeting the cancer. Given the known cardiotoxicities of some established chemotherapies and the possibility that newer approaches may damage the heart, oncologists, cardiologists and imaging specialists now work together to detect and minimize the risk of treatment-induced heart failure.

ASE says new data may be a “wake-up call” to recognize the value of echocardiography.  

The American Society of Echocardiography (ASE) and GE Healthcare have teamed to provide a cardiovascular ultrasound training event for healthcare providers caring for underserved populations in rural northwest India.

There is growing concern among cardiac sonographers about the amount of radiation exposure they experience on the job and few say their workplace has a formal policy to address radiation safety for sonographers, according to a survey conducted by the American Society of Echocardiography.

The American Society of Echocardiography (ASE) has developed a mobile device application, iASE, which provides summaries of the societys most popular guidelines.

The American Society of Echocardiography (ASE) has published new guidelines to improve the existing norms of the right heart in the July issue of the Journal of the American Society of Echocardiography. The recommended procedures will establish a more uniform method of evaluating the size and function of the right ventricle, said the society.

According to research presented during the 21st annual scientific sessions of the American Society of Echocardiography (ASE) in San Diego this week, cardiac troponin plasma concentrations and longitudinal strain can predict the development of cardiotoxicity in patients treated with anthracyclines and trastuzumab chemotherapies.